Adma Biologics reported $568.69M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
Adma Biologics USD 568.69M 10.31M Sep/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
BioCryst Pharmaceuticals USD 446.42M 10.76M Sep/2025
Minerva Neurosciences USD 28.09M 2.33M Sep/2025
Novavax USD 1.18B 156.66M Sep/2025
Omeros USD 200.57M 34.59M Jun/2025
Takeda JPY 15.41T 938.47B Dec/2025